Remora Wealth

2.9K posts

Remora Wealth banner
Remora Wealth

Remora Wealth

@mindlesstrades

Bringing fully automated, quantitative trading strategies to individual investors. Tweets are not investment advice

Maryland, USA Katılım Ocak 2016
218 Takip Edilen756 Takipçiler
Christian Angermayer
Christian Angermayer@C_Angermayer·
I’ve said this before: I believe consumer biotech will become the most compelling sub-sector within biotech - without question - and one of the most attractive investment opportunities overall. Crucially, I believe a significant share of this value will be captured at the distribution layer - specifically by telehealth platforms such as $HIMS, as well as our own “Live Enhanced” platform, a core business line of the @enhanced_games $ENHA
English
1
0
0
70
Samuel Hume
Samuel Hume@DrSamuelBHume·
How the 2026 run rates of the top AI labs and pharmaceuticals compare 1. Tirzepatide (~$51 B) 2. Anthropic (~$45 B) 3. Semaglutide (~$33 B) 4. Pembrolizumab (~$32 B) 5. Apixaban (~$25 B) 6. OpenAI (~$25 B) 7. Dupilumab (~$20 B) 8. Risankizumab (~$18 B) 9. Daratumumab (~$16 B) 10. Biktarvy (~$14 B) Tech people, come to bio: there are lots of diseases left to solve
TBPN@tbpn

"I think what tech people misunderstand is just the size of the TAM in pharma." @zebulgar says capital will rotate into pharma after AGI: "Anthropic is at what, a $60B run rate? Keytruda, the drug that Merck did in 2019, that one drug's topline is $25B in revenue. Just that one drug." "By the way, once there's AGI, what do you think everybody's going to be focused on afterwards? Everybody's just going to want to live forever. Where do you think the capital is going to rotate into? It's going to rotate into longevity, therapeutics, and manufacturing."

Indonesia
20
59
476
97.1K
TrendSpider
TrendSpider@TrendSpider·
what's the hardest thing about trading?
English
178
2
88
48.8K
Remora Wealth
Remora Wealth@mindlesstrades·
@OmarKelly Because he’s still costing us $100 mil in cap space the next 2 years. Not all failures are equal
English
0
0
0
101
Omar Kelly
Omar Kelly@OmarKelly·
Tua got hurt at the end of 2024. Team didn’t give up on him till Pittsburgh. But why do we have to bring up Tua? Team gave up on Tyreek, Chubb, Waddle, Waller. Tua wasn’t he only one who failed
Will Mims@WillMims7

@OmarKelly The team gave up on tua in 2024.

English
19
3
88
14.4K
Remora Wealth
Remora Wealth@mindlesstrades·
@OmarKelly How is this team worse than last year? They upgraded the most important position. Probably not playoffs, but 8-9 improvement over last year not impossible
English
0
0
0
27
Omar Kelly
Omar Kelly@OmarKelly·
GIF
James Dagg@JamesDagg8

@OmarKelly Mark my words Miami will be the surprise team of 2026. This happens every year and every year the people that cover the league are shocked at teams that over perform. Miami will be that team. Malik Willis is the reason.

ZXX
11
0
19
7.4K
The Factor Report
The Factor Report@PeterLBrandt·
Something major going on in global interest rate markets. The market is basically telling central bankers that countries will need to pay much more for anyone to buy their soon-to-be-worthless debt $ZB_F $GBL_F Follow The Factor Report for the latest trading thoughts #av_section_6" target="_blank" rel="nofollow noopener">peterlbrandt.com/#av_section_6
The Factor Report tweet mediaThe Factor Report tweet media
English
33
55
420
66.2K
Remora Wealth
Remora Wealth@mindlesstrades·
@dampedspring Not sure how equity prices can outperform is the only way to kill inflation is for asset prices to decline.
English
0
0
0
271
Andy Constan
Andy Constan@dampedspring·
Over four years ago before QT even started I described how QT could and would be muted based on Treasury issuance policy and coined the term higherer for longerer island where rates stay high and inflation doesn't die. I mistakenly assumed the Fed actually understood the monetary policy impact of their balance sheet policy AND recently wrongly assumed Bessent would care about inflation and act to term out the debt. As every cruise ship (not affected by the rare hantacession virus) steams at full speed to H4L island let me remind you that hikes won't kill inflation. Only asset price declines caused by bond term premium expansion fueled by duration issuance will kill inflation. Until the policymakers finally accept their utter failure to understand the impact of their balance sheet we will have substantially above target inflation and equity will outperform bonds and cash but USD will be weak and Gold and ROW stocks will outperform US stocks.
English
16
7
125
12.1K
cinesthetic.
cinesthetic.@TheCinesthetic·
What’s a sex scene that genuinely mattered to the plot and couldn’t be removed from the film?
English
3.2K
194
14.7K
20.4M
Adam May
Adam May@A_May_MD·
This is what the “$HIMS will be the go-to partner for big pharma!!!” Bull cases look like, BTW. It’s a low margin referral business. That’s it. $HIMS made a ton of money last year by pushing the laws on compounding. That’s it. There was no secret sauce or proprietary edge. They were just willing to bend and break rules that other public companies weren’t. Works until it doesn’t. Now that they can’t pirate sema IP anymore, they get a tiny cut from the legitimate partnership or they don’t get anything from sema at all. That’s what the options should’ve been all along. The “big pharma partner” thesis is stupid. Period. It is not an upside case. Especially because there isn’t any other pharma product ever before, and there will never be another pharma product ever again, that consumers wish to buy with cash more than the GLP-1 class. This was lightening in a bottle. Nobody is buying their ulcerative colitis drugs with cash from $HIMS. I’ll say it again - the pharma partner thesis is stupid, even for sema, but ESPECIALLY for everything else. Let’s see if $HIMS can recapture the grift upside from the (equally stupid) peptide craze. I wouldn’t discount their ability and willingness to grift to make a buck there (hell, they were willing to sell their customers INERT oral semaglutide - scammers). If there’s an upside case for $HIMS it’s that there’s probably nobody better positioned to profit off of the peptide grift. Let’s see if Dudum can get retail to rally around that.
Adam May@A_May_MD

$HIMS YoY growth is lower than the 10Y yield and y’all were telling me I was wrong about assigning it lower multiples this time last year because it was a “gRoWtH sToCk WiTh TeCh MuLtIpLeS” 🥱

English
16
5
77
30.5K
Andy Constan
Andy Constan@dampedspring·
So let's tweak this to within 1%? Of ATH and fewer than 65% Above there averages. See all the red dot signals? Do you understand how this is such nonsense. It's designed to show a particular outcome. Data mining
Andy Constan tweet media
Kevin Gordon@KevRGordon

Per @bespokeinvest: The only precedent for when the S&P 500 has been at record highs while fewer than 60% of stocks were above both their 50- and 200-day moving averages: December 1998-March 2000.

English
12
4
106
29K
Remora Wealth
Remora Wealth@mindlesstrades·
Rarely see over bought reversals on a Monday...at least ones that hold. Probably get a better opportunity later this week if looking to short $SMH $MU $SNDK
English
0
0
1
142
PBA
PBA@801010athlete·
Everyone seems to be taking about the 90’s as a precedent. Think precedents likely out window w this market. We are in the 4th Industrial Revolution, if any precedent makes sense it’s probably the 1920’s.
English
16
5
111
15.2K
Remora Wealth
Remora Wealth@mindlesstrades·
@ZeeContrarian1 Interpersonal relations will be more valuable than ever. Give consumers personalized experiences and you’ll make money
English
0
0
6
606
Z
Z@ZeeContrarian1·
𝗛𝗼𝘄 𝘁𝗼 𝗕𝗲𝗰𝗼𝗺𝗲 𝗥𝗶𝗰𝗵 𝗶𝗻 𝟮𝟬𝟮𝟲 I keep seeing videos on YouTube and TikTok of people in their 20s asking people in their 70s how they became rich. In my opinion, there’s very little value in that, because most of the methods that made people wealthy decades ago are no longer relevant to the current generation. I asked my semi-billionaire friend, who started as a salaried employee at a tech company, what a young person today needs to do to get to where he is now. What’s interesting is that he’s not a programmer and doesn’t know how to code. He opened around 20 businesses, became extremely wealthy, almost lost everything, started again from scratch, and eventually became a semi-billionaire. Because his businesses evolved together with the world and adapted to every major shift happening today, I thought he was a very good person to ask about what young people should study now, or what people who already finished their studies should focus on. I asked him because my nephew just turned 18, and I wanted to know what I should recommend to him. It’s important to understand that some industries that were available to my generation, like trading, are no longer the same opportunities for the next generation. The same way that selling shovels during the gold rush, or digging for oil, became irrelevant to later generations. That’s why it matters who you take advice from. There’s no point asking successful businessmen in certain old industries how they made it, because that road is now almost impossible to travel. The real question is: what road is actually possible today? So I called my friend and asked him directly: “What would you recommend to a young person today who wants to become wealthy?” He said, first of all, get a MacBook. A small MacBook. Then learn the absolute shit out of vibe coding. He said that’s the single most important skill right now. He told me the world is going to split into two types of people: people who run businesses with AI, and people who provide them service. Then he said something else interesting. He said the broader the degree, the better. A degree in business that includes some physics, some programming, some business, some contractual law, a bit of microeconomics and macroeconomics, and teaches you how different systems connect together. At the end of the day, the main thing is to learn how to vibe code. And while learning to vibe code, learn the skills that allow you to create whatever you want, which requires a broader understanding of the world and how the world actually works. Not narrow specialization. Broad understanding combined with the ability to use AI tools at the highest possible level.
Z tweet media
English
11
15
212
14.3K
Remora Wealth
Remora Wealth@mindlesstrades·
Everyone seems to be comparing this rally to the dotcom era. I just don't see it. The froth was everywhere back then. IPOs through the roof. To me, this rally is much closer to 2007-08. One sector with unsustainable growth trajectory and growing systemic risks because of it.
English
0
0
1
91
Remora Wealth
Remora Wealth@mindlesstrades·
I’m in the bear camp for how this all turns out longer term but this market is still going higher first. Market probably pauses next week or two but going to head higher going into summer. $SPY $SMH
Remora Wealth tweet media
English
0
0
3
114
Scott Redler
Scott Redler@RedDogT3·
What does this $spy monthly chart tell you?
Scott Redler tweet media
English
64
7
73
39.9K
Remora Wealth
Remora Wealth@mindlesstrades·
While I believe demand for compute exists and is growing fast, I have very serious doubts that we have the capacity to build data centers as fast as currently being projected. That would seem where the real bottleneck will be. Won't matter until it does, but good luck buying $SMH
English
0
0
1
100
Remora Wealth
Remora Wealth@mindlesstrades·
@HulkCapital @bryan_johnson GLP stands for Glucagon Like peptide 1. There is no such thing as GLP-3. Reta also targets GIP and Glucagon which means it has 3 hormone agonist.
English
0
0
0
55
Bryan Johnson
Bryan Johnson@bryan_johnson·
What peptide should I test next?
Bryan Johnson@bryan_johnson

People mistakenly believe peptides are only good. Peptides can be bad, too. They can cause adverse effects. Some dangerous. I did a peptide experiment and measured its effects in my body. The results are complicated. I tried a peptide called CJC-1295. It pushed my growth hormone up by ~8x. That’s good. That’s what it was supposed to do. But, it also came with adverse effects: > increased my morning fasted blood sugar up 20% > increased stress hormone by 12% > tanked my REM sleep by 23% > made my pancreas work 53% harder and was still losing to rising blood glucose > increased my insulin resistance by 50% These were the most obvious side effects, and I only ran a very narrow panel for this experiment. So I’m sure there’s more. I stopped after two doses, without even reaching the intended target dose. For those of you new to peptides, your body sends instructions to itself using tiny chemical messengers called peptides. There are thousands of them. For example, GLP-1s are drugs that take an existing class of short-lived peptides and modify them to extend their activity duration, which turns them into drugs, following rigorous clinical testing. CJC-1295 is one of those peptide-drugs. It tells your brain to release more growth hormone. Growth hormone is your body's signal to build muscle, repair tissue, and recover. However, and like most grey market peptides, CJC-1295 did not succeed its clinical trial, and hence never became an “official” drug. There is a version called CJC-1295 with DAC. DAC is an attachment glued onto the peptide that makes it last for days in your body instead of hours. One shot, longer effect, just like GLP-1s. Why people use it: more growth hormone could mean better recovery, leaner body, faster healing. The experiment I completed. Two injections a week of CJC-1295 with DAC: > 1.2 mg > 1.8 mg 48 hours after the first injection I was nearly comatose. It felt like severe jet lag, the type you’d feel after traveling nine time zones. My sleep was wrecked and I felt continuously awful. My REM sleep dropped by 23%. REM is when your brain processes memories and repairs itself. Less time for my brain to repair itself. During the experiment, I never felt rested and always fatigued. Why we chose CJC-1295 with DAC. Some will say we picked the wrong peptide. They will say I should have used a different version, CJC-1295 without DAC, mixed with another peptide called Ipamorelin. We went with CJC-1295 with DAC instead as it has the most controlled studies. CJC-1295 with DAC has 2 controlled trials in healthy adults. Ipamorelin alone has 1 controlled trial in healthy adults, plus 1 study that failed when they tried it on bowel surgery patients. The mix of the two has zero controlled trials. On Ipamorelin, it copies a chemical called ghrelin, the one that makes you hungry. On its own it gives you a quick burst of growth hormone that fades fast. It does not keep your longer acting growth signal (called IGF-1) up. Clinics mix Ipamorelin with CJC-1295 no-DAC because the two together are supposed to work better. But we don’t know if that’s accurate because we don’t have trial data. This is a problem with peptides. Almost none of them have been tested properly. We are flying blind. Most of what people use is based on what someone said online, what a clinic claims, or what a friend reports from their subjective feelings. Peptides have the potential to be great when well-studied.

English
444
5
431
210K